Dosing Recommendation for Inositol Trispyrophosphate (ITPP)
Based on the available evidence, ITPP dosing for improving oxygen delivery has been established in clinical trials at 12,390 mg/m² as the maximum tolerated dose, administered as an 8-hour infusion given 9 times over 3 weeks (3 infusions per week). 1
Clinical Context and Evidence Base
The question asks about a powder formulation providing 3000mg per 10g serving, but this dosing format does not align with established clinical protocols. ITPP is an allosteric hemoglobin modulator that shifts the oxygen dissociation curve rightward, enhancing oxygen release to hypoxic tissues. 2, 3
Established Clinical Dosing Protocol
The only human clinical trial data available comes from a Phase Ib dose-escalation study in cancer patients: 1
- Dose range tested: 1,866-14,500 mg/m²/dose
- Maximum tolerated dose: 12,390 mg/m²
- Administration route: 8-hour intravenous infusion
- Frequency: 9 infusions over 3 weeks (typically 3 per week)
- Primary toxicity: Hypercalcemia (mostly requiring little or no intervention)
Mechanism and Rationale
ITPP functions by entering red blood cells and modifying hemoglobin properties to facilitate oxygen release in hypoxic conditions. 2, 3 This mechanism has demonstrated:
- Enhanced oxygen delivery capacity in preclinical models 2, 3
- Increased maximal exercise capacity in mice 4
- Protection from heart failure and improved left ventricular remodeling post-myocardial infarction in rat models 3
Critical Safety Considerations
The powder formulation described (3000mg per 10g) lacks any clinical validation and should not be used. The evidence base consists exclusively of intravenous administration protocols. 1
Key pharmacokinetic findings from animal studies show: 5
- Peak plasma concentration at 5 minutes post-IV administration
- Plasma detection up to 6 hours
- Urinary detection up to 24 hours
- Rapid clearance profile
Current Clinical Status
ITPP is currently in Phase 2 clinical trials for various tumors. 2 Its use for cardiovascular disease or exercise enhancement remains investigational with no approved dosing outside research protocols. 2, 3
For any consideration of ITPP use, patients must be enrolled in approved clinical trials using the established IV infusion protocol at doses up to 12,390 mg/m² per the Phase Ib study parameters. 1 Oral or powder formulations have no safety or efficacy data and represent unapproved, potentially dangerous use.
Human studies demonstrate that 52% of patients achieved disease stabilization with ITPP monotherapy, with treatment-related toxicities being manageable. 1 However, this was in a controlled clinical trial setting with appropriate monitoring for hypercalcemia and other adverse effects.